# Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

> **NCT06584812** · PHASE1 · COMPLETED · sponsor: **Tianjin Institute of Pharmaceutical Research Co., Ltd** · enrollment: 14 (actual)

## Conditions studied

- Acute Coronary Syndrome
- Ischemic Stroke

## Interventions

- **DRUG:** Tiprogrel
- **DRUG:** Tiprogrel
- **DRUG:** Clopidogrel
- **DRUG:** Ticagrelor

## Key facts

- **NCT ID:** NCT06584812
- **Lead sponsor:** Tianjin Institute of Pharmaceutical Research Co., Ltd
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-09
- **Primary completion:** 2024-12-05
- **Final completion:** 2024-12-17
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06584812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06584812, "Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06584812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*